Compare Johnson & Johnson (JNJ) vs Under Armour Inc Class A (UA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Johnson & Johnson vs Under Armour Inc Class A — how do they compare? Johnson & Johnson trades at $260.51 (market cap $626.09B), while Under Armour Inc Class A trades at $5.09 (market cap $2.26B). The key difference: Johnson & Johnson is far larger — about 277× Under Armour Inc Class A's market cap, and Johnson & Johnson pays a 2.06% dividend while Under Armour Inc Class A pays none. Which is the better fit depends on your goals.
| JNJ | UA | |
|---|---|---|
Market Cap | $626.09B | $2.26B |
Volume | 6,156,228 | — |
Sector | Health | Consumer Cyclical |
52-Week High | $267.24 | $7.88 |
52-Week Low | $172.78 | $3.96 |
Enterprise Value | $654.37B | $3.24B |
Dividend Yield | 2.06% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Johnson & Johnson (JNJ) trades at $260.88, down 0.36% today, with a bullish technical signal supported by moving averages. The stock shows strong profitability with a net margin of 21.48% and ROE of 25.74%, though valuations like a P/E of 30.14 appear elevated. Recent earnings beat expectations in Q1 and Q2 2026, and the company maintains a 64-year dividend growth streak, with analyst consensus leaning bullish.
Outlook remains positive with a consensus price target of $284.50, offering potential upside, but risks include legal challenges and high debt-to-asset ratio of 24.06% in 2025. Investors benefit from steady dividends and defensive positioning in healthcare, though valuation multiples may limit near-term gains amid economic uncertainty.
Under Armour (UA) is trading at $5.12, down 9.78% with bearish technical signals despite some oversold RSI readings. The company faces significant fundamental challenges with negative net income margins (-9.99%) and declining revenue trends from $5.16B in 2025 to $4.9B in 2026. Recent Q1 2027 results showed a revenue decline of 3% to $1.1B, prompting management to lower full-year revenue guidance amid softer consumer demand in key markets.
The outlook remains challenging with persistent profitability issues and negative cash flow trends. While analyst sentiment shows mixed ratings (38.81% Buy, 49.25% Hold), the stock trades at attractive valuation multiples (P/S 0.45) but faces execution risks in its turnaround strategy. Key risks include competitive pressures, inventory management challenges, and macroeconomic headwinds affecting consumer spending.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →About Under Armour Inc Class A
Under Armour is a leading inventor, marketer, and distributor of branded athletic performance apparel, footwear, and accessories. Built on the 'technical' performance of synthetic fabrics, the company is currently undergoing a multi-year brand evolution centered on premium product innovation, operational rigor, and a renewed focus on its North American core under the guidance of founder Kevin Plank.
Read more on UA →
